[1]褚小慧.慢性乙型肝炎患者血清HBV DNA,HBeAg和ALT滴度与恩替卡韦疗效的关系[J].现代检验医学杂志,2015,30(02):142-143.[doi:10.3969/j.issn.1671-7414.2015.02.045]
　ZHU Xiao-hui.Relationship between the Level of HBV DNA,ALT and the Titers of HBeAg with Effects of Entecavir in Chronic Hepatitis B Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):142-143.[doi:10.3969/j.issn.1671-7414.2015.02.045]
点击复制

慢性乙型肝炎患者血清HBV DNA,HBeAg和ALT滴度与恩替卡韦疗效的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年02期
页码:
142-143
栏目:
检验与临床
出版日期:
2015-03-20

文章信息/Info

Title:
Relationship between the Level of HBV DNA,ALT and the Titers of HBeAg with Effects of Entecavir in Chronic Hepatitis B Patients
作者:
褚小慧
扬州市江都区滨江人民医院,江苏扬州 225211
Author(s):
ZHU Xiao-hui
Jiangdu Binjiang District People's Hospital of Yangzhou City,Jiangsu Yangzhou 225211,China
关键词:
乙型肝炎;  HBeAg;  滴度;  HBV DNA
分类号:
R512.62; R446
DOI:
10.3969/j.issn.1671-7414.2015.02.045
文献标志码:
A
摘要:
目的 通过检测血清HBV DNA,ALT和HBeAg滴度变化来预测恩替卡韦(ETV)治疗慢性乙型肝炎的临床疗效。方法 60例慢性乙型肝炎患者接受ETV 0.5 mg/d,采用实时荧光定量PCR法检测服药后3,6和12个月时HBV DNA,ALT阴转率; 采用免疫化学发光法检测血清治疗前后HBeAg滴度的变化。结果治疗12个月时,血清ALT复常率,HBeAg阴转率,HBeAg转换率分别为91.7%,86.7%和16.7%; 患者基线HBeAg滴度与疗程3个月时HBeAg滴度下降幅度与远期的HBeAg转换率明显相关,HBeAg的基线滴度越低,HBeAg血清转换越高,与其他各组差异有统计学显著性意义; HBeAg滴度下降幅度≥90%的患者的HBeAg转换率明显高于<90%的患者,与其他各组差异有统计学显著性意义。结论 通过检测HBeAg滴度下降幅度可以早期预测ETV治疗HBeAg阳性CHB患者的HBeAg血清转换率。
Abstract:
Objective To evaluate the efficiency of entecavir in chronic hepatitis B(CHB)patients.Meathods 60 cases of patients treated with entecavir 0.5 mg/d.Observed the negative rate of HBV DNA and ALT after 3,6 and 12 months.Used immuno chemiluminescence to observe the HBeAg titer after medication.Results The negativerate of ALT and HBeAg,HBeAg conversion rate were 91.7%,86.7% and 16.7%,respectively.The titer of HBeAg was low at baseline,the patients would had higherHBeAg seroconversion,there were significant differences with other groups.Thetiter of HBeAg decreased ≥90% patients was significantly higher in patients with <90% on the 3 months.Conclusion The HBeAg titer couldbe predicted ETV for treatment of HBeAg positive CHB patients.

参考文献/References:

[1] 中华医学会肝病学分会,感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. Chinese Society of Hepatology and Chinese Society of Infections Disease,Chinese Medical Association.The guideline of prevention and treatment forchronic hepatitis B[J].Chin J Hepatol,2005,13(12):881-891.
[2] Chang TT,Gish RG,deMan R.et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.
[3] 姚光弼,张定风,王宝恩,等.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究[J].中华肝脏病杂志,2005,13(7):454-458. Yao GB,Zhang DF,Wang BE,et al.A study of the dosage and efficasyof entecavir for treating hepatitis B virus[J].Chin J Hepatol,2005,13(7):454-458.
[4] Hoskote SS,Joshi SR,Chosh AK.Disorders of potassium homeostasi:pathophysiology and management[J].J Assoc Physicians India,2008,56(6):685-693.
[5] Lu FM,Zhuang H.Management of hepatitis B in China[J].Chin Med J,2009,122(1):3-4.
[6] 占国清,谭华炳,张薇薇,等.替比夫定治疗HBeAg阳性慢性乙型肝炎疗效的预测指标[J].临床肝胆病杂志,2011,27(6):608-610. Zhan GQ,Tan HB,Zhang WW,et al.The factors predicing the efficacyof telbivudine in the treatment of HBeAg positive chronic hepatitis B[J].J Clin Hepatol,2011,27(6):608-610.
[7] 叶芳丽,张平安,杨相升,等.HBV感染者血清中HBeAg,HBeAb与Pre-S1抗原的相关性研究[J].现代检验医学杂志,2012,27(5):45-46. Ye FL,Zhang PA,Yang XS,et al.Research on the relationship between HBeAg,HBeAb and Pre-S1 antigen in patients with HBV infection[J].J Mod Lab Med,2012,27(5):45-46.

相似文献/References:

[1]何涛君,吴正林,钟小强,等.乙肝患者HBV载量与IgA,IgG,IgM及C3,C4相关性研究[J].现代检验医学杂志,2015,30(04):67.[doi:10.3969/j.issn.1671-7414.2015.04.018]
　HE Tao-jun,WU Zheng-lin,ZHONG Xiao-qiang,et al.Study on the Relationship between Patients with Hepatitis B Viral Loads and Immunoglobulin A,G,M and Complement C3,C4[J].Journal of Modern Laboratory Medicine,2015,30(02):67.[doi:10.3969/j.issn.1671-7414.2015.04.018]
[2]黄 允,李 艳,彭 锐,等.HBV感染致肝损伤患者CRP,hsCRP和SAA临床价值的探讨[J].现代检验医学杂志,2017,32(02):49.[doi:10.3969/j.issn.1671-7414.2017.02.013]
　HUANG Yun,LI Yan,PENG Rui,et al.Clinical Significance of SAA,CRP and hsCRP in HBV Hepatopathy Patients[J].Journal of Modern Laboratory Medicine,2017,32(02):49.[doi:10.3969/j.issn.1671-7414.2017.02.013]

备注/Memo

备注/Memo:
作者简介:褚小慧(1977-),女,本科,主管技师,研究方向:分子生物学检验,Tel:15952568565,E-mail:chuan226@126.com。
更新日期/Last Update: 2015-03-20